Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Liabilities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Total Liabilities for 6 consecutive years, with $54.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 41.96% to $54.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.3 million through Dec 2025, down 41.96% year-over-year, with the annual reading at $54.3 million for FY2025, 41.96% down from the prior year.
  • Total Liabilities for Q4 2025 was $54.3 million at Relay Therapeutics, down from $62.3 million in the prior quarter.
  • The five-year high for Total Liabilities was $168.9 million in Q3 2022, with the low at $38.6 million in Q1 2021.
  • Average Total Liabilities over 5 years is $101.9 million, with a median of $95.8 million recorded in 2021.
  • Peak annual rise in Total Liabilities hit 202.81% in 2021, while the deepest fall reached 80.94% in 2021.
  • Over 5 years, Total Liabilities stood at $110.6 million in 2021, then skyrocketed by 35.18% to $149.6 million in 2022, then tumbled by 38.5% to $92.0 million in 2023, then grew by 1.66% to $93.5 million in 2024, then tumbled by 41.96% to $54.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $54.3 million, $62.3 million, and $63.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.